| Asthma
Dulera vs Trelegy Ellipta
Side-by-side clinical, coverage, and cost comparison for asthma.Deep comparison between: Dulera vs Trelegy Ellipta with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsTrelegy Ellipta has a higher rate of injection site reactions vs Dulera based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Trelegy Ellipta but not Dulera, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Dulera
Trelegy Ellipta
At A Glance
Oral inhalation
Twice daily
ICS/LABA combination
Oral inhalation
Once daily
ICS/LAMA/LABA
Indications
- Asthma
- Chronic Obstructive Airway Disease
- Asthma
Dosing
Asthma (>=12 years) 2 inhalations twice daily of DULERA 100 mcg/5 mcg or 200 mcg/5 mcg via oral inhalation; maximum 2 inhalations of 200 mcg/5 mcg twice daily (800 mcg/20 mcg per day).
Asthma (5 to <12 years) 2 inhalations of DULERA 50 mcg/5 mcg twice daily via oral inhalation; maximum daily dose 200 mcg/20 mcg.
Chronic Obstructive Airway Disease 1 actuation of TRELEGY ELLIPTA 100/62.5/25 mcg once daily by oral inhalation; rinse mouth with water without swallowing after each dose.
Asthma 1 actuation of TRELEGY ELLIPTA 100/62.5/25 mcg or 200/62.5/25 mcg once daily by oral inhalation; rinse mouth with water without swallowing after each dose.
Contraindications
- Primary treatment of status asthmaticus or acute episodes of asthma requiring intensive measures
- Known hypersensitivity to mometasone furoate, formoterol fumarate, or any ingredient in DULERA
- Primary treatment of status asthmaticus or other acute episodes of COPD or asthma where intensive measures are required
- Severe hypersensitivity to milk proteins or demonstrated hypersensitivity to fluticasone furoate, umeclidinium, vilanterol, or any excipient
Adverse Reactions
Most common (>=3%) Nasopharyngitis, sinusitis, headache; dysphonia reported at 4-5% in long-term (52-week) treatment; influenza, upper respiratory tract infection in pediatric patients aged 5 to <12 years.
Serious Serious asthma-related events (hospitalizations, intubations, death), cardiovascular and CNS effects, Candida albicans infection, immunosuppression, hypercorticism and adrenal suppression, growth effects in pediatrics, glaucoma and cataracts.
Postmarketing Angina pectoris, cardiac arrhythmias (atrial fibrillation, ventricular extrasystoles, tachyarrhythmia), vision blurred, anaphylactic reaction, angioedema, severe hypotension, rash, pruritus, QT prolongation, blood pressure increased, hypokalemia, hyperglycemia, asthma aggravation (cough, dyspnea, wheezing, bronchospasm).
Most common (>=1%) Headache, back pain, nasopharyngitis, upper respiratory tract infection, bronchitis, dysgeusia, cough, oropharyngeal pain, diarrhea, influenza, sinusitis, oral candidiasis, arthralgia, dysphonia, pneumonia, urinary tract infection, rhinitis, constipation, gastroenteritis
Serious Serious asthma-related events (hospitalizations, intubations, death), oropharyngeal candidiasis, pneumonia in COPD, immunosuppression and risk of infections, hypercorticism and adrenal suppression, paradoxical bronchospasm, cardiovascular effects, reduction in bone mineral density, worsening of narrow-angle glaucoma, worsening of urinary retention
Postmarketing Palpitations, blurred vision, eye pain, glaucoma, intraocular pressure increase, hypersensitivity reactions (anaphylaxis, angioedema, rash, urticaria), hyperglycemia, muscle spasms, tremor, anxiety, dysuria, urinary retention
Pharmacology
DULERA combines mometasone furoate, a synthetic corticosteroid with potent anti-inflammatory activity that inhibits multiple cell types and inflammatory mediators involved in the asthmatic response, and formoterol fumarate, a selective long-acting beta2-adrenergic receptor agonist (LABA) that relaxes bronchial smooth muscle by stimulating adenyl cyclase and inhibiting mast cell mediator release.
TRELEGY ELLIPTA combines fluticasone furoate (ICS), umeclidinium (long-acting muscarinic antagonist), and vilanterol (LABA); fluticasone furoate reduces airway inflammation via glucocorticoid receptor activation, umeclidinium produces bronchodilation through M3 muscarinic receptor inhibition, and vilanterol relaxes bronchial smooth muscle through beta2-adrenergic receptor stimulation and increased cyclic AMP.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Dulera
- Covered on 5 commercial plans
- PA (5/12) · Step Therapy (5/12) · Qty limit (10/12)
Trelegy Ellipta
- Covered on 5 commercial plans
- PA (1/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Dulera
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (2/8)
Trelegy Ellipta
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Humana
Dulera
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (2/3) · Qty limit (3/3)
Trelegy Ellipta
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Dulera.
No savings programs available for Trelegy Ellipta.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
DuleraView full Dulera profile
Trelegy ElliptaView full Trelegy Ellipta profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.